Access is the central tenet to the success of lenacapavir as a form of preexposure prophylaxis (PrEP), according to Jeremiah Johnson, the executive director of PrEP4All and Mitchell Warren, the ...

Discover key insights from Gilead Sciences' Q2 2025 earnings call, featuring Yeztugo's groundbreaking launch, upward guidance revisions, and strong ...

Recent developments in antiretroviral therapy (ART) include longer-acting therapies that don't require a daily oral pill and ...

(Nasdaq: GILD) announced today its second quarter 2025 results of operations. "This was a very successful second quarter for Gilead, including the FDA approval for Yeztugo as the world’s first ...

In a small trial across ten U.S. research sites, a novel HIV vaccine candidate has shown a result that has eluded scientists ...

Health Minister Aaron Motsoaledi told Bhekisisa’s TV show, Health Beat, in July, that he “would strongly consider” a ministerial advisory committee (MAC), like the one we had during the COVID pandemic ...

The very sayings that once shaped our conduct could be reimagined to reshape our mindsets: “Do not sweep the house at night, ...

Scientific breakthroughs are fueling new hope in women’s health. But experts warn that persistent gaps in funding and access could stall that progress.

A study on long-acting ART shows 92% viral suppression among HIV-1 viremia patients in the U.S. South, offering hope for high ...

GILD eyes Q2 gains as demand for HIV drugs holds strong despite pricing pressures and cell therapy headwinds. We recommend ...

CHICAGO — Chicago-area groups that support LGBTQ+ individuals are navigating an uncertain landscape while bracing for federal funding cuts that could affect HIV care and prevention.

As Wall Street embarks on the first full week of August, the earnings wave continues with another stacked week of reports ...